Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Position Lessened by Nuveen Asset Management LLC

Nuveen Asset Management LLC trimmed its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 31.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 359,572 shares of the company's stock after selling 162,291 shares during the period. Nuveen Asset Management LLC owned about 0.26% of Vir Biotechnology worth $2,639,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Barclays PLC lifted its position in shares of Vir Biotechnology by 1.3% during the third quarter. Barclays PLC now owns 550,186 shares of the company's stock worth $4,121,000 after purchasing an additional 7,287 shares in the last quarter. KBC Group NV raised its position in shares of Vir Biotechnology by 136.5% in the 4th quarter. KBC Group NV now owns 8,970 shares of the company's stock valued at $66,000 after purchasing an additional 5,177 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Vir Biotechnology by 11.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 29,202 shares of the company's stock valued at $214,000 after buying an additional 2,922 shares during the last quarter. abrdn plc acquired a new stake in shares of Vir Biotechnology during the fourth quarter worth approximately $2,666,000. Finally, State of Alaska Department of Revenue grew its position in shares of Vir Biotechnology by 33.0% during the fourth quarter. State of Alaska Department of Revenue now owns 202,441 shares of the company's stock worth $1,485,000 after buying an additional 50,199 shares in the last quarter. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Vir Biotechnology news, CEO Backer Marianne De sold 79,712 shares of the business's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total transaction of $474,286.40. Following the completion of the transaction, the chief executive officer now directly owns 769,505 shares of the company's stock, valued at $4,578,554.75. The trade was a 9.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 16.00% of the stock is owned by company insiders.

Analysts Set New Price Targets

VIR has been the topic of several recent analyst reports. The Goldman Sachs Group cut their price target on shares of Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Needham & Company LLC restated a "buy" rating and issued a $14.00 target price on shares of Vir Biotechnology in a research note on Thursday, May 22nd. Barclays increased their price target on shares of Vir Biotechnology from $26.00 to $31.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Finally, HC Wainwright reiterated a "buy" rating and issued a $110.00 price target on shares of Vir Biotechnology in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $32.86.

Vir Biotechnology Price Performance

Shares of NASDAQ:VIR traded up $0.30 during trading on Friday, reaching $5.45. 1,332,442 shares of the company's stock traded hands, compared to its average volume of 1,390,999. The stock has a market capitalization of $753.40 million, a P/E ratio of -1.39 and a beta of 1.24. Vir Biotechnology, Inc. has a 12 month low of $4.32 and a 12 month high of $14.45. The company has a 50 day moving average of $5.37 and a 200-day moving average of $7.43.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.05). The company had revenue of $3.03 million during the quarter, compared to analyst estimates of $8.59 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business's revenue was down 94.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.48) earnings per share. Equities research analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).